本刊讯()日前在第八届科博会的展览会上,百泰生物药业有限公司展示了其癌症治疗新药——泰欣生TM重组人源化抗人表皮生长因子受体单克隆抗体。该药是近日获得批准我国第一个具有自主知识产权的治疗性基因工程人源化单抗,其技术水平之高居国际领先地位。据悉泰欣生TM能够如导弹 Benxi hearing () recently in the Eighth Expo Fair, 100 Thai Biological Pharmaceutical Co., Ltd. demonstrated its new drug for cancer treatment - Taixin Health TM recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody. The drug is recently approved by China’s first independent intellectual property rights of therapeutic genetically engineered humanized monoclonal antibody, its technical level of the highest in the international leader. It is reported that Teshin Health TM can be like missiles